JANX Q3 2022 Earnings — Janux Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

JANXJanux Therapeutics, Inc.

$852M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+56.4% YoY

Gross Profit

-$12M-657.7% margin

Operating Income

-$18M-994.0% margin

Net Income

-$17M-920.9% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

-23.3%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$16M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$376M

Total Liabilities

$44M

Stockholders' Equity

$332M

Cash & Equivalents

$65M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$1M	+56.4%
Gross Profit	-$12M	-$7M	-64.5%
Operating Income	-$18M	-$11M	-65.3%
Net Income	-$17M	-$11M	-55.1%